The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial.
Robert R. McWilliams
No relevant relationships to disclose
Michelle R. Mahoney
No relevant relationships to disclose
Benjamin T. Marchello
No relevant relationships to disclose
Aminah Jatoi
No relevant relationships to disclose
Keith D. Krewer
No relevant relationships to disclose
Matthew M. Ames
No relevant relationships to disclose
Daniel Jay Schneider
No relevant relationships to disclose
Grant R. Seeger
No relevant relationships to disclose
Rex B. Mowat
No relevant relationships to disclose
Steven R. Alberts
No relevant relationships to disclose
Matthew P. Goetz
No relevant relationships to disclose